Article info
PDFClinical and epidemiological research
Extended report
Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry
- Correspondence to Dr Bente Glintborg, Department of Rheumatology, Gentofte University Hospital, Niels Andersensvej 65, Hellerup 2900, Denmark; glintborg{at}dadlnet.dk
Citation
Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry
Publication history
- Received April 26, 2012
- Accepted July 19, 2012
- First published August 31, 2012.
Online issue publication
March 10, 2021
Article Versions
- You are viewing the most recent version of this article.
- Previous version (10 March 2021).
- latest version (10 March 2021).
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions